SVB Leerink Maintains Outperform on IsoPlexis, Raises Price Target to $20
SVB Leerink analyst Puneet Souda maintains IsoPlexis (NASDAQ:ISO) with a Outperform and raises the price target from $17 to $20.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
SVB Leerink Initiates Coverage On IsoPlexis with Outperform Rating, Announces Price Target of $17
SVB Leerink analyst Puneet Souda initiates coverage on IsoPlexis (NASDAQ:ISO) with a Outperform rating and announces Price Target of $17.
Morgan Stanley Initiates Coverage On IsoPlexis with Overweight Rating, Announces Price Target of $16
Morgan Stanley analyst Tejas Savant initiates coverage on IsoPlexis (NASDAQ:ISO) with a Overweight rating and announces Price Target of $16.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
